Glecaprevir/pibrentasvir

Drug Profile

Glecaprevir/pibrentasvir

Alternative Names: 2DAA; ABT-493/ABT-530

Latest Information Update: 23 Feb 2017

Price : $50

At a glance

  • Originator AbbVie
  • Class Antivirals; Aza compounds; Benzimidazoles; Carbamates; Cyclic ethers; Cyclopentanes; Cyclopropanes; Fluorobenzenes; Piperidines; Pyrrolidines; Quinoxalines; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Hepatitis C

Most Recent Events

  • 15 Feb 2017 AbbVie initiates a phase IIIb trial for Hepatitis C treatment in USA and Canada (PO, Tablet) (NCT02966795)
  • 02 Feb 2017 Glecaprevir/pibrentasvir receives priority review status for Hepatitis C treatment in USA
  • 02 Feb 2017 US FDA accepts NDA for glecaprevir/pibrentasvir for Hepatitis C treatment for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top